Charles River (NYSE: CRL) to Release Q4 Results Feb. 18 at 7:00 AM ET
- Charles River will release Q4 results on Feb. 18, 2026 at 07:00 AM ET.
- The announcement flags when Charles River posts financial statements, management commentary and supplemental exhibits.
- Monitor Charles River’s investor-relations page and SEC EDGAR after 07:00 AM ET for the press release and 8‑K.
Charles River Sets Q4 Disclosure for Feb. 18 at 07:00
Charles River Laboratories International is announcing its fourth-quarter results release for Feb. 18, 2026 at 07:00 AM ET, providing a precise timestamp for when the company posts its consolidated results and accompanying materials. The brief notice identifies the issuer as Charles River (NYSE: CRL) and specifies the quarter and clock time, flagging when stakeholders can access the firm’s official financial statements, management commentary and any supplemental exhibits that normally accompany quarterly reports. That timestamp also signals when the company is likely to file regulatory disclosures such as a Form 8-K and publish investor-relations packets on its website.
The scheduled release typically includes an income statement, balance sheet, cash flow details and management discussion and analysis that analysts and clients use to assess operational performance across Charles River’s service lines. For a contract research organization focused on preclinical and early-stage drug-development services, these reports provide detail on revenue split by segment, capacity utilization, and trends in outsourced research demand. Even in the absence of specific figures in the notice, the timing allows market participants, customers and partners to align their calendars and prepare questions for any subsequent investor call or management briefings if those are arranged.
Setting a firm publication time also serves compliance and transparency functions, ensuring simultaneous public access to material information. For industry observers, the Q4 disclosure window is a focal point for gauging momentum in the CRO sector, supply-chain pressures at laboratory operations, and shifts in client spending patterns among pharmaceutical and biotech customers that rely on Charles River’s preclinical testing, discovery and safety-assessment services.
Access and Next Steps
Stakeholders seeking the full disclosure are advised to monitor Charles River’s investor-relations page and the SEC’s EDGAR system shortly after 07:00 AM ET on Feb. 18 for the press release and any filed 8-K, as well as any slide decks or supplemental schedules that accompany the results.
Preparation for Stakeholders
Analysts, corporate clients and research partners use the release timing to coordinate model updates, regulatory reporting and operational planning; if an earnings call is scheduled, attendees will likely receive a dial-in or webcast link following the posted announcement.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…